(Adnkronos) - “AbbVie conferma il suo interesse in tre maggiori indicazioni terapeutiche nell'ambito del oftalmologia: in quella dell'occhio secco e in quella delle malattie della retina e nel glaucoma e in particolare nel glaucoma. È un portfolio ricco che guarda all'esperienza di malattia del paziente, sia con retinopatia diabetica sia con glaucoma o con la patologia dell'occhio secco. Avendo soluzioni a 360 gradi per l'organo”. Così, Annalisa Iezzi, Medical Director di AbbVie Italia, parlando di Maculopatia, retinopatia diabetica, glaucoma e dell'impegno di AbbVie a riguardo.
Category
🗞
NewsTranscript
00:00ABVI confirms its interest in three major therapeutic indications in the field of ophthalmology,
00:10in that of the dry eye, in that of the diseases of the retina, so we speak of diabetic retinopathy,
00:17and in glaucoma.
00:18In particular, in glaucoma, ABVI has a therapeutic presidium for every moment of the patient
00:24in glaucoma, so from the drops in mono- or combo-therapy, up to the devices able to
00:32put the patient in the center and reduce the frequency of supply.
00:36It is a rich portfolio that looks at the patient's disease experience, both with diabetic retinopathy,
00:44both with glaucoma or with the pathology of the dry eye, having solutions at 360 degrees
00:50for the organ.
00:51Prevention in this area is fundamental.
00:53We have just named diabetic retinopathy, and it is an area in which ABVI is absolutely
00:58aware that for the patient's well-being it is important to act as soon as possible.
01:02If we think that the guidelines require an annual check for diabetic patients,
01:08but unfortunately in our reality less than 20% do the annual screening.
01:13And that is why we have implemented locally projects in partnership with
01:18the Association of Diabetic Patients that allow us to promote, invite them and book
01:24the screening for them by doing the exam of the ocular background every year.
01:28In all three therapeutic guidelines, ABVI has a rich pipeline.
01:32As regards the dry eye, there are innovative molecules that combine the current effectiveness
01:38requested by doctors, better well-being on the part of the patient, therefore better
01:42comfort in delivery and less side effects.
01:45As regards glaucoma, as we said, even though there are solutions that can accompany the
01:51patient in the weight in days, the further evolution is to have the traditional molecule
01:57of which the effectiveness is recognized and confirmed, but in the form of a device that
02:01allows one or two administrations per year to maintain the effectiveness regardless
02:07of the patient's adherence, thus facilitating it.
02:11The real novelty is in the field of retinal diseases, so both in senile and humid maculopathy
02:17and in diabetic retinopathy, of which we know a strong incidence and prevalence, ABVI
02:24is bringing the innovation of gene therapy.
02:27At the moment, in Italy, 10 centers are experimenting with gene therapy for this.
02:34ABVI's commitment is to protect the eye.
02:37It is therefore about working together with the scientific community and patient associations
02:43to ensure that there is the right solution for each patient, but there is also a commitment
02:47on the part of the patients.
02:49Our support is to continue to offer and invite periodic screening, so the invitation
02:56is recurring to the entire diabetic population to have periodic eye examinations, and ABVI
03:02supports the eye examinations in partnership with scientific societies and patient associations
03:08to be sure to be able to intervene at the right time with the right drug.